|
|
Article: Organogenesis critic seen target of SEC probe
- Article from:
- The Boston Globe (Boston, MA)
- Article date:
- April 16, 1996
- Author:
CopyrightCopyright 1996 The Boston Globe. Provided by ProQuest LLC. (Hide copyright information)
|
Evan Sturza, one of the most ardent critics of Organogenesis Inc.
-- the Canton developer of laboratory-grown skin to treat patients
with venous ulcers -- is reportedly under investigation for unusual
short-selling trading last year.
Sturza, the 34-year-old editor and publisher of the New York-based
Sturza Medical Investment Letter, said the Securities and Exchange
Commission and the US Attorney have asked for his 1995 trading
records involving Organogenesis.
Last Friday, Business Week reported the SEC, the Chicago Board
Options Exchange and the US Attorney's office in Brooklyn are
examining whether Sturza and other short sellers collaborated to
drive down the price of Organogenesis. ...